Atara Biotherapeutics
ATRA
74 hedge funds and large institutions have $695M invested in Atara Biotherapeutics in 2015 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 38 increasing their positions, 5 reducing their positions, and 8 closing their positions.
660% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 5
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
51% more capital invested
Capital invested by funds: $461M → $695M (+$234M)
40% more funds holding
Funds holding: 53 → 74 (+21)
60% less call options, than puts
Call options by funds: $543K | Put options by funds: $1.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$21.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14M |
| 3 |
1WCM
12 West Capital Management
New York
|
+$7.13M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$10.5M |
| 2 |
BAMCO Inc
New York
|
-$5.22M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.64M |
| 4 |
Citigroup
New York
|
-$1.19M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.04M |
ATRA Hedge Fund Activity: Q2 2015 in Review
74 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2015, worth a combined $695M — up 51% from $461M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ATRA positions and 8 closed out — a net gain of 21 holders — while 38 added to existing stakes and 5 trimmed.
The largest buyer was UBS AM, adding an estimated $21.4M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $10.5M sold.
- 74 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2015, up from 53 in Q1 2015.
- Funds reported $695M of Atara Biotherapeutics stock for Q2 2015, up 51% quarter-over-quarter.
- 29 funds opened new Atara Biotherapeutics positions in Q2 2015 and 8 closed out, a net change of +21 holders.
- The largest Atara Biotherapeutics buyer in Q2 2015 was UBS AM, an estimated $21.4M added.
- The largest Atara Biotherapeutics seller in Q2 2015 was EverPoint Asset Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2015.